Co-Diagnostics, Inc. Initiates Vector Control Program in Dominican Republic
January 30 2018 - 6:30AM
Business Wire
Program received enthusiastically by
regional Ministries of Health
Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular
diagnostics company with a unique, proprietary platform for the
development of diagnostic tests, announced today the completion of
a sales and validation trip to the Dominican Republic, including
the initiation of a vector control diagnostics program to track the
spread and distribution of tropical diseases across mosquito
populations.
Vector is the term used to describe an organism that transmits
infectious disease across human or animal populations. Ministries
and Departments of Health in the U.S. and worldwide currently have
vector control services to control, limit, or eradicate vectors
where they are suspected to contribute to the spread of pathogens
or outbreaks.
Co-Diagnostics’ vector control program will involve the
Company’s diagnostic tests being used by vector control services to
test mosquito populations where the insect is known to act as a
vector. The program has been met with enthusiasm by the Ministries
of Health in several Caribbean countries anxious to use it to track
outbreaks of Zika virus, tuberculosis, Malaria, West Nile virus,
Chikungunya virus, and dengue among others.
Tests that are not intended to diagnose humans are subject to
different regulatory requirements, which will allow those used in
the Company’s program to be sold throughout the United States
without 510(k) clearance or Premarket Authorization (“PMA”) from
the FDA, as well as allow for simpler export procedures out of the
U.S. to the Caribbean and other regions. Sales are expected to
begin worldwide following Q2 2018 and successful completion of the
initial program.
In addition to the vector control program, the Company and a
regional marketing and distribution partner completed a number of
sales and product validation site visits to hospitals and clinical
laboratories across the Dominican Republic.
Co-Diagnostics CEO Dwight Egan remarked, “Ever since we became
aware of the interest in pairing disease detection with vector
control programs, we have felt strongly that Co-Diagnostics would
be an ideal partner to provide this support. The feedback and
enthusiasm we have seen for such a product has provided us
encouragement to proceed with the initial program. We are confident
that the market for our tests will expand as we successfully
execute on that program. We were also encouraged by the demand for
our tests at the various hospitals and clinical laboratories we met
with during our time in the DR. We look forward to fully developing
all these opportunities.”
About Co-Diagnostics,
Inc.
Co-Diagnostics, Inc., a Utah corporation, is a molecular
diagnostics company that has developed and intends to manufacture
and sell reagents used for diagnostic tests that function via the
detection and/or analysis of nucleic acid molecules (DNA or RNA),
and to sell diagnostic equipment from other manufacturers as
self-contained lab systems.
Forward-Looking
Statements
This press release contains forward-looking statements.
Forward-looking statements can be identified by words such as
"believes," "expects," "estimates," "intends," "may," "plans,"
"will" and similar expressions, or the negative of these words.
Such forward-looking statements are based on facts and conditions
as they exist at the time such statements are made and predictions
as to future facts and conditions. Readers of this press release
are cautioned not to place undue reliance on any forward-looking
statements. The Company does not undertake any obligation to update
any forward-looking statement relating to matters discussed in this
press release, except as may be required by applicable securities
laws.
Disclaimer
This news release does not constitute an offer to sell or a
solicitation of an offer to buy the securities described herein,
nor shall there be any sale of these securities in any state or
jurisdiction in which such an offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20180130005530/en/
Company Contact:Co-Diagnostics, Inc.Andrew
BensonCo-Diagnostics Investor
Relations801-438-1036investors@codiagnostics.comorInvestor
Contact:Lytham PartnersJoe Diaz,
602-889-9700codx@lythampartners.com
Co Diagnostics (NASDAQ:CODX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Co Diagnostics (NASDAQ:CODX)
Historical Stock Chart
From Apr 2023 to Apr 2024